CA3250514A1 - ANTI-INTERLEUKIN-4 (IL-4R) RECEPTOR ANTIBODIES - Google Patents
ANTI-INTERLEUKIN-4 (IL-4R) RECEPTOR ANTIBODIESInfo
- Publication number
- CA3250514A1 CA3250514A1 CA3250514A CA3250514A CA3250514A1 CA 3250514 A1 CA3250514 A1 CA 3250514A1 CA 3250514 A CA3250514 A CA 3250514A CA 3250514 A CA3250514 A CA 3250514A CA 3250514 A1 CA3250514 A1 CA 3250514A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical formulation
- stable liquid
- liquid pharmaceutical
- concentration
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263337532P | 2022-05-02 | 2022-05-02 | |
| US63/337,532 | 2022-05-02 | ||
| PCT/US2023/020660 WO2023215267A1 (en) | 2022-05-02 | 2023-05-02 | Anti-interleukin-4 receptor (il-4r) antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3250514A1 true CA3250514A1 (en) | 2023-11-09 |
Family
ID=86609834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3250514A Pending CA3250514A1 (en) | 2022-05-02 | 2023-05-02 | ANTI-INTERLEUKIN-4 (IL-4R) RECEPTOR ANTIBODIES |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240024472A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4518837A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025516298A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250004863A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119136787A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023263975A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3250514A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024014835A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316264A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024013496A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202406572A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215267A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025017034A1 (en) * | 2023-07-17 | 2025-01-23 | Formycon Ag | Stable liquid antibody formulation for dupilumab |
| WO2025116637A1 (ko) * | 2023-12-01 | 2025-06-05 | 삼성바이오에피스 주식회사 | 항-IL-4Rα 항체의 안정한 액상 제형 |
| EP4623903A1 (en) * | 2024-03-28 | 2025-10-01 | Fresenius Kabi Deutschland GmbH | Pharmaceutical composition comprising dupilumab |
| KR20260105275A (ko) * | 2024-12-26 | 2026-07-06 | 주식회사 종근당 | 항-hIL-4Rα 항체를 위한 안정화된 액상 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| PT2990420T (pt) | 2000-05-26 | 2017-03-16 | Immunex Corp | Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| UA93653C2 (ru) | 2003-11-07 | 2011-03-10 | Иммунекс Корпорейшн | Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r) |
| CA2664343C (en) | 2006-10-02 | 2016-04-26 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| MX366337B (es) * | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| JP5859148B2 (ja) * | 2012-03-08 | 2016-02-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Aβ抗体製剤 |
| EP2823841A1 (en) | 2013-07-09 | 2015-01-14 | Sanofi-Aventis Deutschland GmbH | Autoinjector |
| RU2689145C2 (ru) * | 2014-04-16 | 2019-05-24 | Биокон Лтд. | Стабильные белковые препараты, содержащие молярный избыток сорбитола |
| AR102198A1 (es) | 2014-10-09 | 2017-02-08 | Regeneron Pharma | Proceso para reducir partículas subvisibles en una formulación farmacéutica |
| TW201707738A (zh) | 2015-06-03 | 2017-03-01 | 賽諾菲阿凡提斯德意志有限公司 | 注射器支架及自動注射器(二) |
| TW201711716A (zh) | 2015-06-03 | 2017-04-01 | 賽諾菲阿凡提斯德意志有限公司 | 護罩鎖 |
| TW201709941A (zh) | 2015-06-03 | 2017-03-16 | 賽諾菲阿凡提斯德意志有限公司 | 聲響指示器(二) |
| TW201711713A (zh) | 2015-06-03 | 2017-04-01 | 賽諾菲阿凡提斯德意志有限公司 | 藥物輸送裝置(五) |
| TW201707741A (zh) | 2015-06-03 | 2017-03-01 | 賽諾菲阿凡提斯德意志有限公司 | 針頭護罩之抓握器、蓋子、自動注射器及製造抓握器之方法 |
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| CN110540590B (zh) | 2018-05-29 | 2023-08-18 | 康诺亚生物医药科技(成都)有限公司 | 一种自免疫抑制物的开发和应用 |
| MX2021001143A (es) | 2018-08-24 | 2021-04-12 | Jiangsu Hengrui Medicine Co | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. |
| KR102330596B1 (ko) | 2018-11-09 | 2021-11-26 | 아주대학교산학협력단 | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 |
| CN111494626B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
| SG11202107007VA (en) | 2018-12-27 | 2021-07-29 | Akeso Biopharma Inc | Antibody against human il-4ra and use thereof |
| CN111592597B (zh) | 2019-05-29 | 2022-04-26 | 山东博安生物技术股份有限公司 | 白介素4受体(il-4r)结合蛋白及其用途 |
-
2023
- 2023-05-02 EP EP23727738.9A patent/EP4518837A1/en active Pending
- 2023-05-02 IL IL316264A patent/IL316264A/en unknown
- 2023-05-02 US US18/142,196 patent/US20240024472A1/en active Pending
- 2023-05-02 AU AU2023263975A patent/AU2023263975A1/en active Pending
- 2023-05-02 JP JP2024564817A patent/JP2025516298A/ja active Pending
- 2023-05-02 TW TW112116324A patent/TW202406572A/zh unknown
- 2023-05-02 WO PCT/US2023/020660 patent/WO2023215267A1/en not_active Ceased
- 2023-05-02 CN CN202380038045.5A patent/CN119136787A/zh active Pending
- 2023-05-02 KR KR1020247039194A patent/KR20250004863A/ko active Pending
- 2023-05-02 CA CA3250514A patent/CA3250514A1/en active Pending
-
2024
- 2024-10-30 CO CONC2024/0014835A patent/CO2024014835A2/es unknown
- 2024-10-31 MX MX2024013496A patent/MX2024013496A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240024472A1 (en) | 2024-01-25 |
| AU2023263975A1 (en) | 2024-12-12 |
| CN119136787A (zh) | 2024-12-13 |
| EP4518837A1 (en) | 2025-03-12 |
| WO2023215267A1 (en) | 2023-11-09 |
| MX2024013496A (es) | 2024-12-06 |
| KR20250004863A (ko) | 2025-01-08 |
| TW202406572A (zh) | 2024-02-16 |
| CO2024014835A2 (es) | 2025-03-06 |
| JP2025516298A (ja) | 2025-05-27 |
| IL316264A (en) | 2024-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6456470B2 (ja) | 抗pcsk9抗体を含む安定化製剤 | |
| JP6053886B2 (ja) | 抗インターロイキン6受容体(il−6r)抗体を含有する安定化製剤 | |
| US20240024472A1 (en) | Anti-Interleukin-4 Receptor (IL-4R) Antibody Formulations | |
| KR101867279B1 (ko) | 항―인터류킨―4 수용체(il-4r) 항체를 함유하는 안정화된 제형 | |
| US20230346929A1 (en) | Stabilized Formulations Containing Anti-IL-33 Antibodies | |
| US20220031843A1 (en) | Stabilized Formulations Containing Anti-CTLA-4 Antibodies | |
| KR20230165828A (ko) | 항-MUC16 x 항-CD3 이중특이적 항체를 함유하는 안정화된 제형 | |
| KR20220113417A (ko) | 항-CD20 x 항-CD3 이중 특이적 항체를 함유한 안정화 제제 | |
| WO2024182636A1 (en) | Anti-fel d1 antibody formulations | |
| CN121464156A (zh) | 含有抗bcma x抗cd3双特异性抗体的稳定调配物 | |
| HK40096835A (en) | Stabilized formulations containing anti-pcsk9 antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241024 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20241024 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241024 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241209 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241209 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241209 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241210 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241210 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241220 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250422 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250422 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260421 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260421 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260527 |